Trial
NCT01838499
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
ICON plc; Covance; PHT Corporation
Condition
Hidradenitis Suppurativa
Intervention
MEDI8968
Why stopped
At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-09-01